BioCentury
ARTICLE | Company News

Veloxis submits Envarsus NDA

December 31, 2013 1:07 AM UTC

Veloxis Pharmaceuticals A/S (CSE:VELO) submitted an NDA to FDA for Envarsus tacrolimus (formerly LCP-Tacro) to prevent organ rejection in kidney transplant patients. An MAA for the product is under re...